Balance Sheet

Accounts Payables Accumulated Expenses Assets Capital Leases Cash & Current Investments Cash & Equivalents Common Equity Convertible Debt Current Assets Current Deferred Revenue Current Deferred Tax Assets Current Leases Current Taxes Finished Goods Goodwill Goodwill & Intangibles Intangibles Inventory Liabilities and Shareholders Equity Long-Term Deferred Tax Long-Term Investments Non-Current Assets Non-Current Debt Non-Current Deferred Tax Liability Non-Current Deffered Revenue Operating Leases Other Accumulated Expenses Other Non-Current Assets Other Non-Current Liabilities Payables Pension Preferred Shares Prepaid Assets Property, Plant & Equipment (Net)Raw Materials Receivables Retained Earnings Shareholder's Equity Shares Outstanding Short term Debt Short-term Investments Total Current Liabilities Total Debt Total Liabilities Total Non-Current Liabilities Treasury Shares Work In Process

Daily Values

Growth Metrics

Others

Supernus Pharmaceuticals (SUPN) Notes Payables (2022 - 2023)

Supernus Pharmaceuticals (SUPN) has disclosed Notes Payables for 2 consecutive years, with $402.5 million as the latest value for Q1 2023.

Quarterly Notes Payables changed N/A to $402.5 million in Q1 2023 from the year-ago period, while the trailing twelve-month figure was $402.5 million through Mar 2023, changed N/A year-over-year, with the annual reading at $402.0 million for FY2022, N/A changed from the prior year.
Notes Payables for Q1 2023 was $402.5 million at Supernus Pharmaceuticals, roughly flat from $402.0 million in the prior quarter.
The five-year high for Notes Payables was $402.5 million in Q1 2023, with the low at $402.0 million in Q4 2022.